Healthcare Triangle, Inc. exhibits a high-risk profile characterized by extreme revenue volatility, evidenced by a 166.1% year-over-year surge in 2026Q1, which fails to translate into operational profitability.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
Company targeting Southeast Asia's largest economy with its Ezovion, Ziloy.ai and neurotechnology platforms and evaluating local partnership and joint venture structures. The targeted pipeline is an internal management estimate and is not contracted revenue or financial guidance.
Malaysia and Indonesia, home to more than 310 million people with a fast-growing need for mental health care, form the initial focus of an initiative combining neuroscience devices, professional education and AI-supported mental healthcare PLEASANTON, Calif., Oct. 26, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced the launch of Neurotechnology AI Devices Sales and Solutions through its wholly owned subsidiary, Quantum Nexis Inc. ("Quantum Nexis"), with strategic healthcare, wellness, neuroscience and public-sector initiatives being actively pursued across Southeast Asia.
A multi-year MSA for EHR optimization and healthcare cybersecurity, MEDITECH-based Rural Health Transformation advisory work in three states, in addition to a new multi-year engagement to support a healthcare business unit's global technology center PLEASANTON, Calif., Oct. 22, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company") today announced that its wholly owned, AI-led subsidiary, Purpose Health, Inc., has signed a series of multi-year agreements.
Healthcare Triangle, Inc. Announces 1-for-20 Reverse Stock Split as Part of Nasdaq Compliance PlanPR NewswirePLEASANTON, Calif., Oct. 21, 2026PLEASANTON, Calif.
Benchmark HCTI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Healthcare Triangle, Inc. (HCTI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.70 | $519.02K | -0.03 | 18.77% | -66.29% | -56.56% | — | |
| $26.00 | $5.8B | -42.42 | 59% | -5.51% | -30.03% | — | |
| $1.46 | $107.89M | -0.55 | 1.48% | -74.24% | -128.24% | — | |
| $8.11 | $15.65M | -2.11 | -8.34% | -6.9% | — | — | |
| $303.73 | $49.34B | 49.40 | 16.34% | 29.34% | 14% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
Healthcare Triangle, Inc. (HCTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Healthcare Triangle, Inc. (HCTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 20, 2026·SEC
Jun 26, 2026·SEC
Get notified when HCTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Healthcare Triangle, Inc. (HCTI) stock FAQ — growth, dividends, profitability & financials explained
Healthcare Triangle, Inc. (HCTI) reported $25.7M in revenue over the trailing twelve months. Revenue was $13.9M in fiscal year 2025. That is 52% less than the $28.7M of fiscal year 2019.
Healthcare Triangle, Inc. (HCTI) grew revenue by 116.4% over the trailing twelve months, compared with the twelve months before.
No. Healthcare Triangle, Inc. (HCTI) reported a net loss of $17.0M over the trailing twelve months.
Healthcare Triangle, Inc. (HCTI) had a return on equity (ROE) of -56.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Healthcare Triangle, Inc. (HCTI) had negative free cash flow of $23.7M over the trailing twelve months.
